Ascletis Pharma Inc. (HKEX: 1672), a China-based innovative R&D driven biotech company, announced on Wednesday that the United States Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ASC11, an oral inhibitor drug candidate aimed at 3-chymotrypsin like protease (3CLpro) for COVID-19.
The company has received approval to study the safety, tolerability and pharmacokinetics of ASC11 at various doses in healthy subjects co-dosed with 100mg ritonavir tablets. The company has produced both ASC11 and ritonavir tablets.
The Phase I clinical trial is to include three cohorts of healthy patients, including single- and multiple-dose escalation studies and a food impact study. The aim of the Phase one trial is to find the right dose to move into the pivotal Phase II/III in COVID-19 patients.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial